Anzeige
Mehr »
Dienstag, 23.06.2026 - Börsentäglich über 12.000 News
SEAS meldet US-Behörden-Compliance und plant neues Kobalt-Projekt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
597 Leser
Artikel bewerten:
(2)

Informa Business Intelligence: Informa Pharma Intelligence Launches New Product Citeline Engage

Citeline Engage will deliver real-world data and customized engagement opportunities to help customers optimize site selection and increase trial efficiencies to accelerate clinical trial timelines

LONDON, Oct. 10, 2019today announces Citeline Engage, a new solution allowing contact research organizations (CROs) and sponsors to optimize site selection and increase trial efficiencies to accelerate clinical trial timelines and enable a faster path to market for drugs. Citeline Engage is a first-to-market solution designed specifically to help optimize protocol development, site feasibility, and, most importantly, increase physician engagement and drive patient awareness to support faster enrollment into clinical trials.

Clinical trials have long been a pain point for industry players, and Citeline Engage is designed to help increase efficiency across a notoriously difficult, yet imperative area, of the pharma industry. Informa Pharma Intelligence's Citeline Engage utilizes real-world data to offer the most efficient outreach services that allow customers to better recruit investigators and patients, optimize trial protocols, and ignite awareness around trials.

By combining trial and investigator intelligence available through Citeline with a verified audience of healthcare professionals through Skipta, Citeline Engage helps CROs and sponsors expedite patient enrollment, drive efficiency and mitigate the risk of trial failure:

  • Investigator Recruitment: Citeline Engage allows clients to accelerate site pre-qualification and recruitment timelines, even when facing saturated markets and rare disease areas.

  • Protocol and Study Design Optimization: Clients can gather direct feedback from physicians, clinical investigators and key opinion leaders to mitigate protocol challenges related to study design or patient recruitment.

  • Trial Awareness: Studies have shown that only a small fraction of patients and healthcare providers are aware that participation in a clinical trial was an option at the time of diagnosis. Citeline Engage ignites awareness of upcoming and ongoing trials through targeted outreach to physicians, clinical investigators and other health care professionals who have access to validated, difficult-to-reach patient populations.

"We have the real-world data to create powerful connections and optimize protocol development, site feasibility, and most importantly physician engagement and patient awareness," said Nicola Marlin, Vice President of Product Development at Informa Pharma Intelligence. "Citeline Engage empowers organizations to create and run the most efficient clinical trials possible through targeting and recruiting top tier investigators and select sites using unique online communities of verified healthcare professionals."

About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products - Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo - to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

Skipta, part of Informa's Pharma Intelligence vertical, is the leading social network of specialized online medical communities for verified healthcare professionals (HCPs). Skipta's growing network of more than 25 specialty communities allow verified HCPs to communicate and collaborate with peers in a focused, secure environment. The company enables pharmaceutical and biotech brands to drive awareness and behavior change by bringing to them multi-channel access to 700,000+ verified HCPs through integrated engagement programs.

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn't covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.

Media Contact
Diffusion PR for Informa Pharma Intelligence
informapharma@diffusionpr.com
646.571.0120

© 2019 GlobeNewswire (Europe)
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.